KUALA LUMPUR, Myriad Genetics Inc announced a collaboration with GSK aimed at improving access to homologous recombination deficiency (HRD) diagnostic testing for high-grade serous ovarian cancer (HGSOC) patients.

A new sponsored testing programme leveraging Myriad’s MyChoice HRD Plus and MyChoice CDx Plus Tests (collectively referred to as Myriad’s MyChoice Tests) is now available in Argentina, Brazil, Chile, Colombia, Egypt, Netherlands, Saudi Arabia, Singapore, and United Arab Emirates.

‘Our collaboration with GSK is an important step forward in providing critical genetic insights that can help clinicians guide more personalised ovarian cancer treatment decisions.

‘In the pursuit of advancing healthcare equity, Myriad is committed to extending the reach of our diagnostic solutions, like Myriad’s MyChoice Tests into additional markets to support more targeted patient care based on their genomic profile,’ said its Executive Vice President of Strategy and Innovation, Patrick Burke in a statement.

This co
llaboration delivers on both companies’ shared commitment to improve care for patients with advanced ovarian cancer by facilitating access to genetic testing and demonstrates a mutual dedication to meeting an unmet need for patients who otherwise may not have access to testing.

HRD testing is an important predictive and prognostic biomarker for patients who have ovarian cancer.

Myriad’s MyChoice Tests determine HRD status in women with ovarian cancer whereby clinicians can order this test through their local pathology labs and samples are sent to Myriad Genetics.

A leader in genetic testing and precision medicine, Myriad Genetics is dedicated to advancing health and well-being for all by developing and offering genetic tests and guide treatment decisions across medical specialties.

Source: BERNAMA News Agency